M Pharmaceutical Inc. (DB:T3F1) signed a letter of intent to acquire M Diagnostics Inc. for approximately $0.2 million on December 2, 2014. The letter of intent calls for a perpetual, worldwide, exclusive license to all the rights to the eMosquito technology owned by M Diagnostics Inc. The consideration $0.15 million on closing, a 3% royalty on the commercial sale of any related products, and issuance of approximately 8.1 million common shares, which are subject to a 3 year escrow, with 10% being immediately releasable, and the balance in 6 equal installments over the next 3 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% |
|
-.--% | +9,900.00% |
2018 | James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc | CI |
2018 | Callitas Health Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.53K | |
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- MPHMF Stock
- News Callitas Health Inc.
- M Pharmaceutical Inc. (DB: T3F1) signed a letter of intent to acquire the intellectual property associated with the eMosquito device by the purchase of M Diagnostics Inc. for approximately $0.2 million.